Zenas Biopharma (usa), Llc

This study aims to see if a new oral medication called orelabrutinib can slow the worsening of disability in people with primary progressive multiple sclerosis (PPMS). About 705 participants will be randomly assigned to receive either the study drug or a placebo for up to 5 years…